Zobrazeno 1 - 10
of 136
pro vyhledávání: '"John H. Glick"'
Publikováno v:
Academic Medicine. 93:220-223
PROBLEM Academic health centers face increasing challenges in pursuing and maintaining clinical excellence in their tripartite mission. At Penn Medicine, an institution-wide strategic planning process was initiated in 2012. Among the recommendations
Autor:
John H. Glick, H.-J. Senn, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Beat Thürlimann
Publikováno v:
Annals of Oncology. 17:1772-1776
St Gallen Expert Consensus meetings update evidence on treatment of early breast cancer every 2 years and interpret its significance for treatment of individual patients. Such interpretation is controversial. Clinical decisions cannot, however, be po
Autor:
H.-J. Senn, Richard D. Gelber, Alan S. Coates, Beat Thürlimann, A. Goldhirsch, John H. Glick, Panel Members
Publikováno v:
Annals of Oncology. 16:1569-1583
The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic therapy for early breast cancer. Rather than the earlier approach commencing with risk assessment
Autor:
Barbara L. Weber, Angela DeMichele, Melissa Klein-Cabral, Phyllis A. Gimotty, Richard Aplenc, Theresa Colligan, Andrea S. Foulkes, Timothy R. Rebbeck, Jeffrey Botbyl, Edward A. Stadtmauer, Lisa Wray, John H. Glick
Publikováno v:
Journal of Clinical Oncology. 23:5552-5559
PurposeAdjuvant chemotherapy cures only a subset of women with nonmetastatic breast cancer. Genotypes in drug-metabolizing enzymes, including functional polymorphisms in cytochrome P450 (CYP) and glutathione S-transferases (GST), may predict treatmen
Autor:
John H. Glick, Lynn M. Schuchter, Angela DeMichele, Karen L. Smith, Kevin Fox, Lisa Wray, Melissa Klein-Cabral
Publikováno v:
Clinical Breast Cancer. 6:260-266
Background Black patients with breast cancer may be at greater risk for chemotherapy-related hematologic toxicity than white patients because of lower baseline blood cell counts. We hypothesize that these baseline differences could lead to excess hem
Autor:
Michael J. O'connell, Sandra J. Horning, John D. Earle, Thomas M. Habermann, John H. Glick, Kyung Mann Kim, Edie Weller
Publikováno v:
Journal of Clinical Oncology. 22:3032-3038
Purpose To compare low-dose (30 Gy) radiotherapy (RT) with observation (OBS) in limited-stage aggressive lymphoma patients achieving complete remission (CR) after chemotherapy, and to measure conversion from partial response (PR) to CR with high-dose
Autor:
Michael Feldman, Kara N. Maxwell, Carolyn E. Clark, Andrea B. Troxel, David B. Lieberman, Angela R. Bradbury, John H. Glick, Danielle Soucier-Ernst, J. Morrissette, Susan M. Domchek, AM DeMichele, Kevin Fox, N Shih, Jennifer M. Matro, K. L. Nathanson, Amy S. Clark, Noah Goodman, Christopher Colameco, Lewis A. Chodosh
Publikováno v:
Cancer Research. 76:P6-07
Background: While several comprehensive genomic sequencing tests are clinically available for breast cancer(BC), little is known about the spectrum of findings reported in the general population and clinical utility of findings for patients(pts). Her
Autor:
John M. Kirkwood, Daniel D. Karp, Joseph G. Ibrahim, John H. Glick, Ernest C. Borden, James A. Stewart, Marian Ewell, Donna Glover
Publikováno v:
Melanoma Research. 13:619-626
This study was designed to evaluate the toxicity and efficacy of cisplatin and WR-2721 in contrast to cisplatin alone for the therapy of measurable metastatic melanoma. Ninety-four patients with metastatic melanoma were randomized to receive either c
Autor:
Helaine Bertsch, Delray Schultz, Eleanor E.R. Harris, Kevin Fox, John H. Glick, Lawrence J. Solin
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 55:1200-1208
Purpose To evaluate the long-term outcome of combined modality therapy for inflammatory breast cancer. Methods and materials The data from 54 women treated between 1983 and 1996 for inflammatory breast cancer were analyzed. Patients with metastatic d